Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.De Novo Pharmaceuticals has entered into a drug discovery partnership agreement with Achaogen, whereby De Novo will apply its new molecular structure generating drug discovery platform targeting pathogenic bacteria.
Subscribe to our email newsletter
Philip Dean, CSO at De Novo, said: “We are very pleased to be working with Achaogen – a leader in the fight against drug-resistant bacteria.”
Phillip Patten, senior vice president, added: “We are pleased to be working with De Novo to expand our lead optimization program, and to help us develop cutting-edge therapeutics that will speed us towards our goal of providing therapies to treat unmet clinical needs caused by multi-drug resistant bacterial infections.”
Financial terms of the agreement were not disclosed.